Floatz logo

tno155

MET Amplification

Massachusetts General HospitalPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the MET Amplification cohort.

Asset / SponsorPhaseRating
Crizotinib
Massachusetts General Hospital
Phase 2BB
Osimertinib
Qingdao Central Hospital
Phase 2B
Toripalimab
Guangdong Provincial People's Hospital
Phase 2CCC
Carboplatin
Guangdong Provincial People's Hospital
Phase 2CCC
Vebreltinib
Apollomics Inc.
Phase 2CCC

View all 10 →

Same molecule, other indications

tno155 is also rated in:

KRAS G12C Mutant Solid TumorsDormant
CC
Indicative ·
45 / 100
View asset →
colorectal carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
lung cancerDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →